ClinicalTrials.gg
CompletedNCT06814119Updated Feb 13, 2026

A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)

A Phase 1 interventional study of Calderasib in Healthy and Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.

Enrollment
10th of 32
34 · median 26
Started
2025
the only one that year
Phase 1
25 of 32
2 open now
Registered
29th of 32
by date

Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 10th largest by enrollment, is the only one that started in 2025, is one of 25 in phase 1, and was the 29th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of calderasib when it is given to people with RI and if people with RI can tolerate it.

03

Conditions studied

  • Healthy
  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

All participants:

- Has a ≥18.0 and ≤40.0 kg/m\^2

Participants with severe or moderate RI:

  • With the exception of RI, is sufficiently healthy for study participation
  • Has stable renal function with no change in renal status at least 29 days prior to dosing and is not currently or has not been previously on dialysis for at least 1 year

Participants with normal renal function:

- Is medically healthy

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

All participants:

  • Has a history of cancer ()
  • Has positive results for , surface antigen, or virus
  • Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing

Participants with severe or moderate RI:

  • Has a history or presence of renal artery stenosis
  • Has a renal transplant or nephrectomy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Panel A: Severe RI

    Participants with severe RI will be administered a single oral dose of calderasib on Day 1 under fasting conditions.

    Drug: Calderasib

  • Experimental
    Panel B: Moderate RI

    Participants with moderate RI will be administered a single oral dose of calderasib on Day 1 under fasting conditions.

    Drug: Calderasib

  • Experimental
    Panel C: Healthy

    Healthy participants will be administered a single oral dose of calderasib on Day 1 under fasting conditions.

    Drug: Calderasib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of calderasib

    Blood samples will be collected to determine the AUC0-inf of calderasib.

    Time frame: At designated timepoints (up to approximately 2 days postdose)

  2. Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of calderasib

    Blood samples will be collected to determine the AUC0-last of calderasib.

    Time frame: At designated timepoints (up to approximately 2 days postdose)

  3. Area Under the Concentration-Time Curve from Time 0 to 24 Hours (AUC0-24) of calderasib

    Blood samples will be collected to determine the AUC0-24 of calderasib.

    Time frame: At designated timepoints (up to 24 hours postdose)

  4. Plasma Concentration of calderasib at 24 Hours Postdose (C24)

    Blood samples will be collected to determine the C24 of calderasib.

    Time frame: At designated timepoints (up to 24 hours postdose)

  5. Maximum Plasma Concentration (Cmax) of calderasib

    Blood samples will be collected to determine the Cmax of calderasib.

    Time frame: At designated timepoints (up to approximately 2 days postdose)

  6. Time to Maximum Plasma Concentration (Tmax) of calderasib

    Blood samples will be collected to determine the Tmax of calderasib.

    Time frame: At designated timepoints (up to approximately 2 days postdose)

  7. Apparent Terminal Half-life (t1/2) of calderasib

    Blood samples will be collected to determine the t1/2 of calderasib.

    Time frame: At designated timepoints (up to approximately 2 days postdose)

  8. Apparent Clearance (CL/F) of calderasib

    Blood samples will be collected to determine the CL/F of calderasib.

    Time frame: At designated timepoints (up to approximately 2 days postdose)

  9. Apparent Volume of Distribution During Terminal Phase (Vz/F) of calderasib

    Blood samples will be collected to determine the Vz/F of calderasib.

    Time frame: At designated timepoints (up to approximately 2 days postdose)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. The number of participants who experience an adverse event will be reported.

    Time frame: Up to approximately 2 weeks

  2. Number of Participants Who Discontinue From the Study Due to an Adverse Event

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. The number of participants who discontinue from the study due to an adverse event will be reported.

    Time frame: Up to approximately 2 weeks

  3. Total Amount of calderasib Excreted Unchanged in Urine (Ae)

    Urine samples will be collected to determine the Ae of calderasib.

    Time frame: At designated timepoints (up to approximately 1 day postdose)

  4. Total Amount of calderasib Excreted Unchanged in Urine From 0 to 24 Hours (Ae0-24)

    Urine samples will be collected to determine the Ae0-24 of calderasib.

    Time frame: At designated timepoints (up to 24 hours postdose)

  5. Fraction of calderasib Excreted Unchanged in Urine (fe)

    Urine samples will be collected to determine the fe of calderasib.

    Time frame: At designated timepoints (up to approximately 1 day postdose)

  6. Renal Clearance (CLr) of calderasib

    Urine samples will be collected to determine the CLr of calderasib.

    Time frame: At designated timepoints (up to approximately 1 day postdose)

07

Study locations

2 sites
  • Orlando Clinical Research Center ( Site 0002)
    Orlando, Florida 32809, United States
  • Research by Design ( Site 0001)
    Chicago, Illinois 60643, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jan 2026, 9 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 7, 2025
StartActual
Apr 7, 2025
Primary completionActual
Jan 23, 2026
CompletionActual
Feb 6, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06814119
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Apr 7, 2025
Primary completion
Jan 23, 2026
Completion
Feb 6, 2026
Last update
Feb 13, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calderasib

Start the discussion